Salvage peptide receptor radionuclide therapy with [<sup>177</sup>Lu-DOTA,Tyr<sup>3</sup>]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.

Eur J Nucl Med Mol Imaging · 2019 · PMC6351514 · PMID 30267116

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, patients with pancreatic NET showed a trend towards a longer OS with a survival benefit of approximately 32 months, although this was not significantly different.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.